Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $5.51
Key levels
Resistance$6.76
Resistance$5.39
Latest news & SEC filings
EarningsTonix Pharmaceuticals holds Q3 2026 earnings call
EarningsTonix Pharmaceuticals Posts Q3 2026 Financial Results
SEC FilingTonix Pharmaceuticals Holding Corp. filed a report on a major company event (Form 8-K)
EarningsTonix Pharmaceuticals Q3 loss of $2.89 per share misses estimates, revenue $17.2M beats
All TNXP news →Tonix Pharmaceuticals is a biopharmaceutical company focused on treatments for the nervous system, immune conditions, infections, and uncommon illnesses. It sells TONMYA for fibromyalgia and two migraine medicines, Zembrace SymTouch and Tosymra, to patients in the United States. Its pipeline covers depression, acute stress, Lyme disease prevention, organ transplant rejection, cocaine overdose, Prader-Willi syndrome, mpox, smallpox, and some cancers. Research and manufacturing sites are located in Maryland and Massachusetts.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
SEPT Low Target
$18.00
SEPT Mid Target
$22.00
SEPT High Target
$26.00
Analyst Consensus
$22.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TNXP.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$24.71
25
Moat Score
NONE
4/9
Piotroski Score
-4.2
Altman Z-Score
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| LEDERMAN SETH | director officer | Buy | 2,000 | $28K | Aug 27, 2026 |
| Taylor Carolyn E. | director | Buy | 1,415 | $15K | Jun 12, 2026 |
| LEDERMAN SETH | director officer | Buy | 5,000 | $59K | Jun 9, 2026 |
| Stillwell Richard Newcomb | director | Buy | 5,000 | $58K | Jun 8, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
29.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
91.75%
FCF Growth YoY
-69.1%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for TNXP, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:39:24 | $3.85 | 2,600 | $$10K | SELL |
| 22:13:48 | $3.95 | 1,500 | $$6K | BUY |
| 21:02:12 | $3.81 | 4,900 | $$19K | SELL |
| 21:00:34 | $3.87 | 1,000 | $$4K | BUY |
| 21:00:01 | $3.87 | 1,172 | $$5K | SELL |
5 dark pool trades shown · $$43K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Tonix Pharmaceuticals Holding Corp. (TNXP) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Tonix Pharmaceuticals Holding Corp. (TNXP) is at $3.24, down 16.28% (-$0.63) at the Nov 12, 2026 close.
Latest TNXP news — Nov 9, 2026: Tonix Pharmaceuticals holds Q3 2026 earnings call · Nov 9, 2026: Tonix Pharmaceuticals Posts Q3 2026 Financial Results
The average analyst price target for TNXP is $22.00, ranging from $18 to $26, based on 3 analysts. Latest: Canaccord Genuity initiates on Oct 26, 2026.
Analyst ratings for TNXP: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
TNXP last reported on Aug 10, 2026: EPS -$2.44 vs -$2.64 expected — a beat of 7.6%.
TNXP does not currently pay a dividend.
Resistance: $5.39, $6.76, $9.40.
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
Nov 9, 2026: Tonix Pharmaceuticals holds Q3 2026 earnings call · Nov 9, 2026: Tonix Pharmaceuticals Posts Q3 2026 Financial Results · Nov 9, 2026: Tonix Pharmaceuticals Holding Corp. filed a report on a major company event (Form 8-K)